- Home
- SOGP vs EVAX Comparison
SOGP vs EVAX Comparison
Compare SOGP & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- EVAX
- Stock Information
- Founded
- SOGP 2010
- EVAX 2008
- Country
- SOGP Singapore
- EVAX Denmark
- Employees
- SOGP N/A
- EVAX N/A
- Industry
- SOGP
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOGP
- EVAX Health Care
- Exchange
- SOGP NYSE
- EVAX Nasdaq
- Market Cap
- SOGP 10.0M
- EVAX 8.7M
- IPO Year
- SOGP 2020
- EVAX 2021
- Fundamental
- Price
- SOGP $2.08
- EVAX $0.91
- Analyst Decision
- SOGP
- EVAX Strong Buy
- Analyst Count
- SOGP 0
- EVAX 2
- Target Price
- SOGP N/A
- EVAX $11.00
- AVG Volume (30 Days)
- SOGP 47.1K
- EVAX 982.0K
- Earning Date
- SOGP 01-01-0001
- EVAX 10-31-2024
- Dividend Yield
- SOGP N/A
- EVAX N/A
- EPS Growth
- SOGP N/A
- EVAX N/A
- EPS
- SOGP N/A
- EVAX N/A
- Revenue
- SOGP $250,401,822.00
- EVAX $3,295,000.00
- Revenue This Year
- SOGP $37.39
- EVAX $4,845.21
- Revenue Next Year
- SOGP $3.88
- EVAX $30.30
- P/E Ratio
- SOGP N/A
- EVAX N/A
- Revenue Growth
- SOGP N/A
- EVAX N/A
- 52 Week Low
- SOGP $1.49
- EVAX $0.83
- 52 Week High
- SOGP $6.70
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- SOGP 54.19
- EVAX 34.78
- Support Level
- SOGP $2.02
- EVAX $0.83
- Resistance Level
- SOGP $2.22
- EVAX $0.96
- Average True Range (ATR)
- SOGP 0.23
- EVAX 0.12
- MACD
- SOGP 0.01
- EVAX 0.03
- Stochastic Oscillator
- SOGP 52.25
- EVAX 20.51
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.